

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Novel systemic therapies in atopic dermatitis: what... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-132/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-132" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?" />
    
            <meta name="og:title" content="F1000Research Article: Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?.">
            <meta name="og:description" content="Read the latest article version by Helen Alexander, Thomas Patton, Zarif K. Jabbar-Lopez, Andrea Manca, Carsten Flohr, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="18628">
            <meta name="article-id" content="17039">
            <meta name="dc.title" content="Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?">
            <meta name="dc.description" content="Patients with atopic dermatitis (AD) who do not adequately respond to topical therapy and phototherapy often need systemic immunomodulatory treatment to control their symptoms. Conventional systemic agents, such as ciclosporin, azathioprine, and methotrexate, have been used for decades, but there are concerns about their safety profile. There are now many novel systemic agents emerging through clinical trials, which may have great potential in the treatment of AD. Despite this, there are very few data comparing the performance of these drugs against each other. The purpose of this article is to review the current systemic therapies in AD and present an indirect comparison of systemic AD treatments using effectiveness and safety data from published randomised controlled trials, highlighting important remaining gaps in knowledge. Although the latest developments in systemic AD treatments are exciting and dearly needed, further work is required before the promise of a therapeutic revolution becomes reality.">
            <meta name="dc.subject" content="Atopic dermatitis, eczema">
            <meta name="dc.creator" content="Alexander, Helen">
            <meta name="dc.creator" content="Patton, Thomas">
            <meta name="dc.creator" content="Jabbar-Lopez, Zarif K.">
            <meta name="dc.creator" content="Manca, Andrea">
            <meta name="dc.creator" content="Flohr, Carsten">
            <meta name="dc.date" content="2019/01/31">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.17039.1">
            <meta name="dc.source" content="F1000Research 2019 8:132">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Atopic dermatitis">
            <meta name="prism.keyword" content="eczema">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/01/31">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="132">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.17039.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-132">
            <meta name="citation_title" content="Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?">
            <meta name="citation_abstract" content="Patients with atopic dermatitis (AD) who do not adequately respond to topical therapy and phototherapy often need systemic immunomodulatory treatment to control their symptoms. Conventional systemic agents, such as ciclosporin, azathioprine, and methotrexate, have been used for decades, but there are concerns about their safety profile. There are now many novel systemic agents emerging through clinical trials, which may have great potential in the treatment of AD. Despite this, there are very few data comparing the performance of these drugs against each other. The purpose of this article is to review the current systemic therapies in AD and present an indirect comparison of systemic AD treatments using effectiveness and safety data from published randomised controlled trials, highlighting important remaining gaps in knowledge. Although the latest developments in systemic AD treatments are exciting and dearly needed, further work is required before the promise of a therapeutic revolution becomes reality.">
            <meta name="citation_description" content="Patients with atopic dermatitis (AD) who do not adequately respond to topical therapy and phototherapy often need systemic immunomodulatory treatment to control their symptoms. Conventional systemic agents, such as ciclosporin, azathioprine, and methotrexate, have been used for decades, but there are concerns about their safety profile. There are now many novel systemic agents emerging through clinical trials, which may have great potential in the treatment of AD. Despite this, there are very few data comparing the performance of these drugs against each other. The purpose of this article is to review the current systemic therapies in AD and present an indirect comparison of systemic AD treatments using effectiveness and safety data from published randomised controlled trials, highlighting important remaining gaps in knowledge. Although the latest developments in systemic AD treatments are exciting and dearly needed, further work is required before the promise of a therapeutic revolution becomes reality.">
            <meta name="citation_keywords" content="Atopic dermatitis, eczema">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Helen Alexander">
            <meta name="citation_author_institution" content="Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK">
            <meta name="citation_author" content="Thomas Patton">
            <meta name="citation_author_institution" content="Centre for Health Economics, University of York, York, UK">
            <meta name="citation_author" content="Zarif K. Jabbar-Lopez">
            <meta name="citation_author_institution" content="Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK">
            <meta name="citation_author" content="Andrea Manca">
            <meta name="citation_author_institution" content="Centre for Health Economics, University of York, York, UK">
            <meta name="citation_author" content="Carsten Flohr">
            <meta name="citation_author_institution" content="Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK">
            <meta name="citation_publication_date" content="2019/01/31">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="132">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.17039.1">
            <meta name="citation_firstpage" content="132">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-132/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-132.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=18628 /> <input type=hidden id=articleId name=articleId value=17039 /> <input type=hidden id=xmlUrl value="/articles/8-132/v1/xml"/> <input type=hidden id=xmlFileName value="-8-132-v1.xml"> <input type=hidden id=article_uuid value=71b2e900-06f6-439c-a93b-e4fa9597b348 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.17039.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.17039.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-132"
  },
  "headline": "Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment...",
  "datePublished": "2019-01-31T10:13:16",
  "dateModified": "2019-01-31T10:13:16",
  "author": [
    {
      "@type": "Person",
      "name": "Helen Alexander"
    },    {
      "@type": "Person",
      "name": "Thomas Patton"
    },    {
      "@type": "Person",
      "name": "Zarif K. Jabbar-Lopez"
    },    {
      "@type": "Person",
      "name": "Andrea Manca"
    },    {
      "@type": "Person",
      "name": "Carsten Flohr"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Patients with atopic dermatitis (AD) who do not adequately respond to topical therapy and phototherapy often need systemic immunomodulatory treatment to control their symptoms. Conventional systemic agents, such as ciclosporin, azathioprine, and methotrexate, have been used for decades, but there are concerns about their safety profile. There are now many novel systemic agents emerging through clinical trials, which may have great potential in the treatment of AD. Despite this, there are very few data comparing the performance of these drugs against each other. The purpose of this article is to review the current systemic therapies in AD and present an indirect comparison of systemic AD treatments using effectiveness and safety data from published randomised controlled trials, highlighting important remaining gaps in knowledge. Although the latest developments in systemic AD treatments are exciting and dearly needed, further work is required before the promise of a therapeutic revolution becomes reality."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-132.html",
            "name": "Novel systemic therapies in atopic dermatitis: what do we need to..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Novel systemic therapies in atopic dermatitis: what do we need to... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=18628 data-id=17039 data-downloads="" data-views="" data-scholar="10.12688/f1000research.17039.1" data-recommended="" data-doi="10.12688/f1000research.17039.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-132/v1/pdf?article_uuid=71b2e900-06f6-439c-a93b-e4fa9597b348" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-17039-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-17039-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-17039-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Alexander H, Patton T, Jabbar-Lopez ZK <em>et al.</em> Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution? [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):132 (<a class=new-orange href="https://doi.org/10.12688/f1000research.17039.1" target=_blank>https://doi.org/10.12688/f1000research.17039.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-17039-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=17039 id=track-article-signin-17039 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/17039?target=/articles/8-132.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=18628 /> <input name=articleId type=hidden value=17039 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:helen.2.alexander@kcl.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Helen Alexander</span></a><a href="https://orcid.org/0000-0002-0241-5408" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-0241-5408</div><sup>1</sup>,&nbsp;</span><span class="">Thomas Patton<sup>2</sup>,&nbsp;</span><span class="">Zarif K. Jabbar-Lopez<sup>1</sup>,&nbsp;</span><span class="">Andrea Manca<sup>2</sup>,&nbsp;</span><span class="">Carsten Flohr<sup>1</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:helen.2.alexander@kcl.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Helen Alexander</span></a><a href="http://orcid.org/0000-0002-0241-5408" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-0241-5408</div><sup>1</sup>,&nbsp;</span><span class="">Thomas Patton<sup>2</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Zarif K. Jabbar-Lopez<sup>1</sup>,&nbsp;</span><span class="">Andrea Manca<sup>2</sup>,&nbsp;</span><span class="">Carsten Flohr<sup>1</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 31 Jan 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.17039.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK<br/> <sup>2</sup> Centre for Health Economics, University of York, York, UK<br/> <p> <div class=margin-bottom> Helen Alexander <br/> <span>Roles: </span> Conceptualization, Formal Analysis, Investigation, Methodology, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Thomas Patton <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Zarif K. Jabbar-Lopez <br/> <span>Roles: </span> Methodology, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Andrea Manca <br/> <span>Roles: </span> Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Carsten Flohr <br/> <span>Roles: </span> Conceptualization, Formal Analysis, Methodology, Project Administration, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=7912-43433></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=44950-43435></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=15319-43434></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Patients with atopic dermatitis (AD) who do not adequately respond to topical therapy and phototherapy often need systemic immunomodulatory treatment to control their symptoms. Conventional systemic agents, such as ciclosporin, azathioprine, and methotrexate, have been used for decades, but there are concerns about their safety profile. There are now many novel systemic agents emerging through clinical trials, which may have great potential in the treatment of AD. Despite this, there are very few data comparing the performance of these drugs against each other. The purpose of this article is to review the current systemic therapies in AD and present an indirect comparison of systemic AD treatments using effectiveness and safety data from published randomised controlled trials, highlighting important remaining gaps in knowledge. Although the latest developments in systemic AD treatments are exciting and dearly needed, further work is required before the promise of a therapeutic revolution becomes reality. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Atopic dermatitis, eczema </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Helen Alexander (<a href="mailto:helen.2.alexander@kcl.ac.uk">helen.2.alexander@kcl.ac.uk</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Helen Alexander </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> CF has received investigator-led research funding from Sanofi for microbiome work. His department has received clinical trial funding from Sanofi and AbbVie to test novel therapeutics in paediatric atopic eczema patients. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the UK Department of Health, or the National Institute of Health Research. HA, TP, AM, and ZKJ-L declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> CF is funded through a UK National Institute for Health Research (NIHR) Career Development Fellowship (CDF-2014-07-037). CF, HA, and ZKJ-L are supported by the NIHR Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Alexander H <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Alexander H, Patton T, Jabbar-Lopez ZK <em>et al.</em> Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution? [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):132 (<a href="https://doi.org/10.12688/f1000research.17039.1" target=_blank>https://doi.org/10.12688/f1000research.17039.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 31 Jan 2019, <b>8</b>(F1000 Faculty Rev):132 (<a href="https://doi.org/10.12688/f1000research.17039.1" target=_blank>https://doi.org/10.12688/f1000research.17039.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 31 Jan 2019, <b>8</b>(F1000 Faculty Rev):132 (<a href="https://doi.org/10.12688/f1000research.17039.1" target=_blank>https://doi.org/10.12688/f1000research.17039.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d39182e207>Introduction</h2><p class="" id=d39182e210>Atopic dermatitis (AD) affects 15–30% of children and 5% of adults and carries profound functional, psychological, and social morbidity<sup><a href="#ref-1">1</a>–<a href="#ref-3">3</a></sup>. Although mild and moderate AD can usually be managed with topical treatments and/or phototherapy, approximately 2% of people with AD require systemic treatments to induce adequate symptom control<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>.</p><p class="" id=d39182e227>We are entering an exciting era, described by some as a therapeutic revolution<sup><a href="#ref-6">6</a>–<a href="#ref-8">8</a></sup>, as dozens of novel systemic treatments are being developed for AD. These targeted biologic and small molecule agents and the conventional systemic immunosuppressive AD treatments provide an increasingly broad range of therapeutic options. Although there is some clinical guidance on when to start systemic therapy, many evidence gaps remain regarding the comparative performance of these drugs<sup><a href="#ref-9">9</a>,<a href="#ref-10">10</a></sup>. Moreover, the lack of a gold standard conventional systemic therapy for AD means there is no benchmark against which to compare the performance of novel agents. Many factors, including the impact on disease severity and quality of life as well as adverse events (AEs) and cost-effectiveness, play into the complex treatment decision-making process when clinicians and patients agree on choosing a particular therapy and in the formulation of treatment guidance produced by stakeholders, such as the UK National Institute for Health and Care Excellence (NICE).</p><p class="" id=d39182e244>Based on a systematic search of the literature, we discuss the latest developments in systemic AD treatments. We present an indirect comparison of novel and conventional systemic AD treatments with regard to treatment efficacy, safety, and cost-effectiveness and highlight important gaps that need to be filled.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d39182e250>Conventional systemic atopic dermatitis treatments</h2><p class="" id=d39182e253>The main conventional systemic treatments for AD are ciclosporin, methotrexate, and azathioprine<sup><a href="#ref-11">11</a>–<a href="#ref-13">13</a></sup>. Mycophenolate mofetil is less commonly used. Some of these agents have been used to treat severe AD for decades despite a lack of robust randomised controlled trial (RCT) evidence. Ciclosporin is a calcineurin inhibitor that inhibits T-cell-dependent immune responses. It has a rapid onset of action with significant improvement in disease severity often seen within a few weeks. However, relapse is commonly seen after treatment withdrawal. Methotrexate is a folic acid antagonist, but its exact mechanism of action in inflammatory diseases, including AD, is not fully understood. It has a relatively slow onset of action, like azathioprine. The latter exerts its anti-inflammatory effects by inhibition of <i>de novo</i> purine synthesis leading to impaired leucocyte proliferation. Anecdotally, azathioprine and methotrexate have the potential to alter the natural history of the disease and induce long-term remission, although there is currently no RCT evidence to confirm this<sup><a href="#ref-14">14</a>–<a href="#ref-16">16</a></sup>. Mycophenolate mofetil blocks <i>de novo</i> guanine synthesis via the inhibition of inosine monophosphate dehydrogenase leading to impaired leucocyte proliferation. The safety profiles of azathioprine and ciclosporin in particular are of concern. Nephrotoxicity and hypertension are the most significant side effects of ciclosporin. As a result, the United States Food and Drug Administration recommends limiting its continuous use to one year in psoriasis patients<sup><a href="#ref-17">17</a></sup>. Azathioprine can cause myelosuppression and carries an increased risk of infection, lymphoma, and non-melanoma skin cancer<sup><a href="#ref-18">18</a>–<a href="#ref-22">22</a></sup>. Methotrexate and mycophenolate mofetil are considered relatively safe medications, but long-term data from AD cohorts are missing at present. In practice, even when a conventional agent is working well in AD, most clinicians feel that these agents cannot be used for years, particularly because of the long-term risk of malignancy. The development of novel agents, with improved long-term safety, is therefore essential.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d39182e291>Novel systemic atopic dermatitis treatments</h2><p class="" id=d39182e294>Thanks to our enhanced understanding of the complex immunological processes in AD skin, there are now many promising treatment targets (<a href="#f1">Figure 1</a>). Dupilumab is an interleukin (IL)-4 receptor α-antagonist that inhibits IL-4 and IL-13 signalling and has been approved in Europe and the United States for the treatment of adults with moderate-to-severe AD. Clinical trials are underway in children. In addition to dupilumab, the IL-13 inhibitors tralokinumab and lebrikizumab and the IL-31 receptor monoclonal antibody nemolizumab have also demonstrated good potential in clinical trials. Fezakinumab, a monoclonal antibody against IL-22, was effective in the treatment of patients with severe AD in a recent phase 2 trial. Janus kinase (JAK) inhibitors are used to treat a range of inflammatory diseases, and data demonstrating their efficacy in AD are now also emerging.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18628/f65151f9-87fc-4fc0-b465-d4732de31fe2_figure1.gif"><img alt="f65151f9-87fc-4fc0-b465-d4732de31fe2_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18628/f65151f9-87fc-4fc0-b465-d4732de31fe2_figure1.gif"></a><div class=caption><h3>Figure 1. Atopic dermatitis pathogenesis and drug targets of novel systemic therapies.</h3><p id=d39182e310>Novel systemic therapies target immune mediators in atopic dermatitis. Mepolizumab is a monoclonal antibody to interleukin-4 (IL-4). Omalizumab is a monoclonal anti-immunoglobulin E (IgE) antibody. Dupilumab is an IL-4 receptor α-antagonist that inhibits IL-4 and IL-13 signalling. Lebrikizumab and tralokinumab are monoclonal antibodies that bind to IL-13. Ustekinumab binds to the shared p40 subunit of IL-12 and IL-23 to regulate T helper type 1 (Th1) and Th17 pathways. Nemolizumab is a monoclonal antibody against IL-31 receptor A. Fezakinumab is an IL-22 antagonist. Baricitinib is a Janus kinase 1 (JAK1) and JAK2 inhibitor. DC, dendritic cell; ILC2, type 2 innate lymphoid cell; LC, Langerhans cell; S. aureus, <i>Staphylococcus aureus</i>; TSLP, thymic stromal lymphopoietin.</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d39182e323>Indirect comparison of atopic dermatitis systemic treatments</h2><p class="" id=d39182e326>As there is a paucity of direct head-to-head trial data comparing treatments in AD, we have indirectly compared the performance of these drugs using data from published RCTs. In our analysis, we have included both blinded and open-label extension RCTs that were published up until 30 September 2018 and report efficacy and safety data of one or more systemic immunomodulatory treatments for moderate-to-severe AD. We have included only the conventional systemic RCTs in which the most commonly used conventional treatments were tested: ciclosporin, methotrexate, azathioprine, and mycophenolate mofetil. We included only trials that used a validated severity measure, such as the Eczema Area and Severity Index (EASI), Scoring Atopic Dermatitis (SCORAD) index, the Six Area Six Sign Atopic Dermatitis (SASSAD) severity score, or the Patient Oriented Eczema Measure (POEM).</p><div class=section><a name=d39182e329 class=n-a></a><h3 class=section-title>Overview of included randomised controlled trials</h3><p class="" id=d39182e334>We included 33 trials (<a href="#T1">Table 1</a>). Most of the trials testing conventional systemic agents were small, and a single phase 3 dupilumab trial enrolled more patients than all the included conventional systemic trials<sup><a href="#ref-23">23</a></sup>. A total of 12 RCTs were head-to-head comparisons and 21 were placebo-controlled trials. The majority (85.7%, 12/14) of the conventional systemic agent trials were head-to-head comparisons, while there are currently no head-to-head trials including novel AD treatments. A diverse range of primary endpoints was used across these studies (<a href="#f2">Figure 2</a>).</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Summary of included randomised controlled trials.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d39182e358 class=n-a></a><thead><a name=d39182e360 class=n-a></a><tr><a name=d39182e362 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d39182e364 class=n-a></a>Author</th><th align=left colspan=1 rowspan=1 valign=top><a name=d39182e367 class=n-a></a>Year</th><th align=left colspan=1 rowspan=1 valign=top><a name=d39182e370 class=n-a></a>Intervention</th><th align=left colspan=1 rowspan=1 valign=top><a name=d39182e373 class=n-a></a>n</th><th align=left colspan=1 rowspan=1 valign=top><a name=d39182e376 class=n-a></a>Study<br class=br>duration<br class=br>(weeks)</th></tr></thead><tbody><a name=d39182e385 class=n-a></a><tr><a name=d39182e387 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e389 class=n-a></a>Harper <i>et al.</i><sup><a href="#ref-25">25</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e397 class=n-a></a>2000</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e400 class=n-a></a>Ciclosporin burst versus<br class=br>continuous therapy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e405 class=n-a></a>40</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e408 class=n-a></a>52</td></tr><tr><a name=d39182e412 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e414 class=n-a></a>Granlund <i>et al.</i><sup><a href="#ref-26">26</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e422 class=n-a></a>2001</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e425 class=n-a></a>Ciclosporin versus UVAB<br class=br>phototherapy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e430 class=n-a></a>38</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e433 class=n-a></a>8</td></tr><tr><a name=d39182e437 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e439 class=n-a></a>Pacor <i>et al.</i><sup><a href="#ref-27">27</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e447 class=n-a></a>2004</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e450 class=n-a></a>Ciclosporin versus tacrolimus</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e453 class=n-a></a>30</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e456 class=n-a></a>8</td></tr><tr><a name=d39182e460 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e462 class=n-a></a>Bemanian <i>et al.</i><sup><a href="#ref-28">28</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e470 class=n-a></a>2005</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e473 class=n-a></a>Ciclosporin versus intravenous<br class=br>immunoglobulin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e478 class=n-a></a>14</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e481 class=n-a></a>12</td></tr><tr><a name=d39182e485 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e487 class=n-a></a>Schmitt <i>et al.</i><sup><a href="#ref-29">29</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e495 class=n-a></a>2010</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e498 class=n-a></a>Ciclosporin versus prednisolone</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e501 class=n-a></a>38</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e504 class=n-a></a>6</td></tr><tr><a name=d39182e509 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e511 class=n-a></a>El-Khalawany <i>et al.</i><sup><a href="#ref-30">30</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e519 class=n-a></a>2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e522 class=n-a></a>Ciclosporin versus methotrexate</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e525 class=n-a></a>40</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e528 class=n-a></a>12</td></tr><tr><a name=d39182e532 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e534 class=n-a></a>Koppelhus <i>et al.</i><sup><a href="#ref-31">31</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e542 class=n-a></a>2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e545 class=n-a></a>Ciclosporin versus extracorporeal<br class=br>photopheresis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e550 class=n-a></a>20</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e553 class=n-a></a>30</td></tr><tr><a name=d39182e557 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e559 class=n-a></a>Jin <i>et al.</i><sup><a href="#ref-32">32</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e567 class=n-a></a>2015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e570 class=n-a></a>Ciclosporin versus ciclosporin +<br class=br>glucosamine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e575 class=n-a></a>38</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e578 class=n-a></a>8</td></tr><tr><a name=d39182e582 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e584 class=n-a></a>Kim <i>et al.</i><sup><a href="#ref-33">33</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e592 class=n-a></a>2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e595 class=n-a></a>Ciclosporin versus ciclosporin +<br class=br>topical therapy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e600 class=n-a></a>60</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e603 class=n-a></a>24</td></tr><tr><a name=d39182e607 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e609 class=n-a></a>Goujon <i>et al.</i><sup><a href="#ref-34">34</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e617 class=n-a></a>2017</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e620 class=n-a></a>Ciclosporin versus methotrexate</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e623 class=n-a></a>97</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e626 class=n-a></a>24</td></tr><tr><a name=d39182e630 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e632 class=n-a></a>Berth-Jones <i>et al.</i><sup><a href="#ref-35">35</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e640 class=n-a></a>2002</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e643 class=n-a></a>Azathioprine versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e646 class=n-a></a>27</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e649 class=n-a></a>12</td></tr><tr><a name=d39182e654 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e656 class=n-a></a>Meggitt <i>et al.</i><sup><a href="#ref-36">36</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e664 class=n-a></a>2006</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e667 class=n-a></a>Azathioprine versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e670 class=n-a></a>41</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e673 class=n-a></a>12</td></tr><tr><a name=d39182e677 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e679 class=n-a></a>Schram <i>et al.</i><sup><a href="#ref-37">37</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e687 class=n-a></a>2011</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e690 class=n-a></a>Azathioprine versus methotrexate</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e693 class=n-a></a>42</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e696 class=n-a></a>12</td></tr><tr><a name=d39182e700 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e702 class=n-a></a>Gerbens <i>et al.</i><sup><a href="#ref-14">14</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e710 class=n-a></a>2018</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e713 class=n-a></a>Azathioprine versus methotrexate</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e716 class=n-a></a>35</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e719 class=n-a></a>260</td></tr><tr><a name=d39182e723 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e725 class=n-a></a>Oldhoff <i>et al.</i><sup><a href="#ref-38">38</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e733 class=n-a></a>2005</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e736 class=n-a></a>Mepolizumab versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e739 class=n-a></a>43</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e742 class=n-a></a>2</td></tr><tr><a name=d39182e746 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e748 class=n-a></a>Iyengar <i>et al.</i><sup><a href="#ref-39">39</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e756 class=n-a></a>2013</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e759 class=n-a></a>Omalizumab versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e762 class=n-a></a>8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e765 class=n-a></a>24</td></tr><tr><a name=d39182e769 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e771 class=n-a></a>Beck <i>et al.</i><sup><a href="#ref-40">40</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e779 class=n-a></a>2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e782 class=n-a></a>Dupilumab versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e785 class=n-a></a>30</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e788 class=n-a></a>4</td></tr><tr><a name=d39182e793 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e795 class=n-a></a>Beck <i>et al.</i><sup><a href="#ref-40">40</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e803 class=n-a></a>2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e806 class=n-a></a>Dupilumab versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e809 class=n-a></a>37</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e812 class=n-a></a>4</td></tr><tr><a name=d39182e816 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e818 class=n-a></a>Beck <i>et al.</i><sup><a href="#ref-40">40</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e826 class=n-a></a>2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e829 class=n-a></a>Dupilumab versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e832 class=n-a></a>109</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e835 class=n-a></a>12</td></tr><tr><a name=d39182e839 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e841 class=n-a></a>Beck <i>et al.</i><sup><a href="#ref-40">40</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e849 class=n-a></a>2014</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e852 class=n-a></a>Dupilumab + topical<br class=br>glucocorticoids versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e857 class=n-a></a>31</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e860 class=n-a></a>4</td></tr><tr><a name=d39182e864 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e866 class=n-a></a>Thaçi <i>et al.</i><sup><a href="#ref-41">41</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e874 class=n-a></a>2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e877 class=n-a></a>Dupilumab versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e880 class=n-a></a>379</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e883 class=n-a></a>16</td></tr><tr><a name=d39182e887 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e889 class=n-a></a>Simpson <i>et al.</i><sup><a href="#ref-23">23</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e897 class=n-a></a>2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e900 class=n-a></a>Dupilumab versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e903 class=n-a></a>671</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e906 class=n-a></a>16</td></tr><tr><a name=d39182e910 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e912 class=n-a></a>Simpson <i>et al.</i><sup><a href="#ref-23">23</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e920 class=n-a></a>2016</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e923 class=n-a></a>Dupilumab versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e926 class=n-a></a>708</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e929 class=n-a></a>16</td></tr><tr><a name=d39182e934 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e936 class=n-a></a>Blauvelt <i>et al.</i><sup><a href="#ref-42">42</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e944 class=n-a></a>2017</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e947 class=n-a></a>Dupilumab versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e950 class=n-a></a>740</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e953 class=n-a></a>52</td></tr><tr><a name=d39182e957 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e959 class=n-a></a>de Bruin-Weller <i>et al.</i><sup><a href="#ref-43">43</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e967 class=n-a></a>2018</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e970 class=n-a></a>Dupilumab versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e973 class=n-a></a>390</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e976 class=n-a></a>16</td></tr><tr><a name=d39182e980 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e982 class=n-a></a>Khattri <i>et al.</i><sup><a href="#ref-44">44</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e990 class=n-a></a>2017</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e993 class=n-a></a>Ustekinumab versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e996 class=n-a></a>33</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e999 class=n-a></a>33</td></tr><tr><a name=d39182e1003 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1005 class=n-a></a>Saeki <i>et al.</i><sup><a href="#ref-45">45</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1013 class=n-a></a>2017</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1016 class=n-a></a>Ustekinumab versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1019 class=n-a></a>79</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1022 class=n-a></a>12</td></tr><tr><a name=d39182e1026 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1028 class=n-a></a>Ruzicka <i>et al.</i><sup><a href="#ref-46">46</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1036 class=n-a></a>2017</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1039 class=n-a></a>Nemolizumab versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1042 class=n-a></a>264</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1045 class=n-a></a>12</td></tr><tr><a name=d39182e1049 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1051 class=n-a></a>Kabashima <i>et al.</i><sup><a href="#ref-47">47</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1059 class=n-a></a>2018</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1062 class=n-a></a>Nemolizumab versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1065 class=n-a></a>191</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1068 class=n-a></a>64</td></tr><tr><a name=d39182e1073 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1075 class=n-a></a>Wollenberg <i>et al.</i><sup><a href="#ref-48">48</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1083 class=n-a></a>2018</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1086 class=n-a></a>Tralokinumab versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1089 class=n-a></a>204</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1092 class=n-a></a>12</td></tr><tr><a name=d39182e1096 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1098 class=n-a></a>Guttman-Yassky <i>et al.</i><sup><a href="#ref-49">49</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1106 class=n-a></a>2018</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1109 class=n-a></a>Fezakinumab versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1112 class=n-a></a>60</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1115 class=n-a></a>10</td></tr><tr><a name=d39182e1119 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1121 class=n-a></a>Guttman-Yassky <i>et al.</i><sup><a href="#ref-50">50</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1129 class=n-a></a>2018</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1132 class=n-a></a>Baricitinib versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1135 class=n-a></a>124</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1138 class=n-a></a>16</td></tr><tr><a name=d39182e1142 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1144 class=n-a></a>Simpson <i>et al.</i><sup><a href="#ref-51">51</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1152 class=n-a></a>2018</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1155 class=n-a></a>Lebrikizumab versus placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1158 class=n-a></a>209</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1161 class=n-a></a>12</td></tr></tbody></table></div><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18628/f65151f9-87fc-4fc0-b465-d4732de31fe2_figure2.gif"><img alt="f65151f9-87fc-4fc0-b465-d4732de31fe2_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18628/f65151f9-87fc-4fc0-b465-d4732de31fe2_figure2.gif"></a><div class=caption><h3>Figure 2. Primary end points of included trials.</h3><p id=d39182e1178>The diverse range of primary endpoints reported across included randomised controlled trials. EASI, Eczema Area and Severity Index; IGA, Investigator’s Global Assessment; PGA, Physician's Global Assessment; SASSAD, Six Area Six Sign Atopic Dermatitis; SCORAD, Scoring Atopic Dermatitis; VAS, visual analogue scale.</p></div></div></div><div class=section><a name=d39182e1186 class=n-a></a><h3 class=section-title>Treatment effectiveness: physician-assessed severity measures</h3><p class="" id=d39182e1191>Different clinical severity score endpoints were reported across the trials (<a href="#SF1">Supplementary Figure 1</a>). Many trials did not report the same scores, even as secondary or experimental endpoints, making indirect comparison of some treatments very difficult. In some cases, the scales of the same score differed across trials, thus further complicating clinical effectiveness comparisons. For instance, the Investigator’s Global Assessment (IGA) score was reported in 22 trials, but some used a five-point Likert scale while others used a six-point scale. Some trials reported the objective SCORAD score, whereas others published the full composite SCORAD index, which includes patient-reported pruritus and sleep disturbance.</p><p class="" id=d39182e1197>We compared the mean percentage change from baseline for EASI and SCORAD for each of the systemic treatments where these data were available (<a href="#f3">Figure 3a and 3b</a>, <a href="#SF2">Supplementary Figure 2a and 2b</a>). We calculated a mean placebo response using pooled data from all novel systemic therapy RCTs. This indirect comparison suggests that ciclosporin at a dose of 2.7–5 mg/kg/day in the short-term and methotrexate and azathioprine in the longer term may perform as well as many of the novel systemic agents. The superior performance of dupilumab compared with ciclosporin (2.5–5 mg/kg/day) in terms of EASI is consistent with another indirect comparison in which logistic regression modelling was used to predict the EASI responses to these treatments<sup><a href="#ref-24">24</a></sup>. However, drug dosing is important, and an indirect comparison of effectiveness, as measured by SCORAD reduction induced by these agents, suggests that ciclosporin at a dose of 5 mg/kg/day may be as effective as dupilumab at least for short-term disease control.</p><a name=f3 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18628/f65151f9-87fc-4fc0-b465-d4732de31fe2_figure3.gif"><img alt="f65151f9-87fc-4fc0-b465-d4732de31fe2_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18628/f65151f9-87fc-4fc0-b465-d4732de31fe2_figure3.gif"></a><div class=caption><h3>Figure 3. Treatment effectiveness: physician-assessed severity measures.</h3><p id=d39182e1220>Eczema Area and Severity Index (EASI) (a) and Scoring Atopic Dermatitis (SCORAD) (b) mean percentage change from baseline up to 16 weeks for systemic agents for which these data were reported. MTX, methotrexate.</p></div></div></div><div class=section><a name=d39182e1228 class=n-a></a><h3 class=section-title>Treatment effectiveness: patient-reported severity measures</h3><p class="" id=d39182e1233>A wide range of patient-assessed measures was reported across the included trials (<a href="#SF3">Supplementary Figure 3</a>). Nemolizumab and dupilumab appear to be superior in improving pruritus compared to the other treatments (<a href="#f4">Figure 4</a>), although the available pruritus score data are very limited, in particular for conventional systemic agents.</p><a name=f4 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18628/f65151f9-87fc-4fc0-b465-d4732de31fe2_figure4.gif"><img alt="f65151f9-87fc-4fc0-b465-d4732de31fe2_figure4.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18628/f65151f9-87fc-4fc0-b465-d4732de31fe2_figure4.gif"></a><div class=caption><h3>Figure 4. Treatment effectiveness: patient-reported severity measures.</h3><p id=d39182e1252>Mean percentage change from baseline in pruritus visual analogue score (VAS) and pruritus numerical rating scale (NRS) for systemic agents for which these data were reported.</p></div></div></div><div class=section><a name=d39182e1261 class=n-a></a><h3 class=section-title>Treatment effectiveness: quality of life</h3><p class="" id=d39182e1266>The Dermatology Life Quality Index (DLQI) was the most widely reported measure of quality of life, although there were several other scores reported across the trials (<a href="#SF4">Supplementary Figure 4</a>). Baricitinib and dupilumab appear to perform best at improving quality of life (<a href="#f5">Figure 5</a>), although DLQI was not reported in most of the conventional systemic trials, thus precluding many of these treatments from the comparison.</p><a name=f5 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18628/f65151f9-87fc-4fc0-b465-d4732de31fe2_figure5.gif"><img alt="f65151f9-87fc-4fc0-b465-d4732de31fe2_figure5.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18628/f65151f9-87fc-4fc0-b465-d4732de31fe2_figure5.gif"></a><div class=caption><h3>Figure 5. Treatment effectiveness: quality of life.</h3><p id=d39182e1285>Dermatology Life Quality Index (DLQI) mean percentage change from baseline for systemic agents for which these data were reported.</p></div></div></div><div class=section><a name=d39182e1293 class=n-a></a><h3 class=section-title>Treatment effectiveness: long-term disease control</h3><p class="" id=d39182e1298>Regarding long-term disease control, there are very few data available on the performance of conventional systemics and no data beyond 64 weeks for the novel systemic agents. Dupilumab and nemolizumab appear to be superior to other treatments up to one year (<a href="#f6">Figure 6</a>). Haeck <i>et al.</i> showed that mycophenolate sodium is also effective at maintaining remission for up to one year, after remission was induced with a six-week course of ciclosporin<sup><a href="#ref-52">52</a></sup>. A five-year follow up study comparing methotrexate and azathioprine was recently published and suggests good long-term effectiveness for both, but patient numbers in each study arm were small<sup><a href="#ref-14">14</a></sup>. The extension study SOLO-CONTINUE (NCT02395133) will provide even longer-term effectiveness data for dupilumab. Importantly, data on clinical effectiveness in terms of inducing and maintaining disease remission off treatment are lacking for any systemic therapy, although anecdotally this has been seen for methotrexate and azathioprine in particular<sup><a href="#ref-14">14</a>–<a href="#ref-16">16</a></sup>.</p><a name=f6 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18628/f65151f9-87fc-4fc0-b465-d4732de31fe2_figure6.gif"><img alt="f65151f9-87fc-4fc0-b465-d4732de31fe2_figure6.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18628/f65151f9-87fc-4fc0-b465-d4732de31fe2_figure6.gif"></a><div class=caption><h3>Figure 6. Treatment effectiveness: long-term disease control.</h3><p id=d39182e1332>Scoring Atopic Dermatitis (SCORAD) mean percentage change from baseline for systemic agents for which these data were reported in at least one trial that was one year or longer in duration.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d39182e1343>Drug safety profiles</h2><div class=section><a name=d39182e1346 class=n-a></a><h3 class=section-title>Short-term safety</h3><p class="" id=d39182e1351>To compare the tolerability and safety of AD systemic treatments, we have calculated the incidence rates per participant per week for AEs and serious AEs (SAEs), as these were defined in individual trials (n = 26). Seven trials either did not provide any AE data or did not provide the data in a form that enabled incidence rate calculation. This highlights the lack of standardisation in safety reporting in clinical trials, limiting robust comparisons across trials. <a href="#T2">Table 2</a> summarises the available safety data from the included studies, showing high variability in the incidence rates reported for the conventional systemic agents. This is most likely due to the small study size and short duration of the included studies. If participant numbers are small in a RCT, then there may be misleadingly low AE reporting, falsely suggesting a more favourable drug safety profile than is seen in clinical practice.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Summary of adverse events.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d39182e1368 class=n-a></a><thead><a name=d39182e1370 class=n-a></a><tr><a name=d39182e1372 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d39182e1374 class=n-a></a>Systemic<br class=br>agent</th><th align=left colspan=1 rowspan=1 valign=top><a name=d39182e1379 class=n-a></a>SAE incidence<br class=br>rate per patient<br class=br>week (%)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d39182e1386 class=n-a></a>AE incidence rate per<br class=br>patient week (%)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d39182e1391 class=n-a></a>Common AEs (clinical trial incidence of ≥1/100)</th></tr></thead><tbody><a name=d39182e1396 class=n-a></a><tr><a name=d39182e1398 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1400 class=n-a></a>Ciclosporin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1403 class=n-a></a>0–2.2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1406 class=n-a></a>0–20.8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1409 class=n-a></a>Serum creatinine increase, hypertension, GI upset, infections, skin<br class=br>infections, headache, fatigue, cramps, paraesthesia, lower limb<br class=br>oedema, hypertrichosis, gingival hyperplasia, anaemia, leukopenia,<br class=br>pancytopenia, thrombocytopenia, ESR increase, liver enzyme increase,<br class=br>magnesium decrease, fever, malaise, AD exacerbation, dyslipidaemia,<br class=br>tremor, flushing, metallic taste</td></tr><tr><a name=d39182e1423 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1425 class=n-a></a>Methotrexate</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1428 class=n-a></a>0.19</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1431 class=n-a></a>9.8–23.5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1434 class=n-a></a>GI upset, infections, liver enzyme increase, skin infections, AD<br class=br>exacerbation, anaemia, leukopenia, pancytopenia, fatigue, headache,<br class=br>renal impairment, fever, malaise</td></tr><tr><a name=d39182e1442 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1444 class=n-a></a>Azathioprine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1447 class=n-a></a>0.03 </td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1450 class=n-a></a>3–22.9</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1453 class=n-a></a>GI upset, URTI, LRTI, fatigue, light-headedness, malaise, headache,<br class=br>folliculitis, skin infections, lymphopenia, neutropenia, liver enzyme<br class=br>increase, AD exacerbation</td></tr><tr><a name=d39182e1461 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1463 class=n-a></a>Mycophenolate<br class=br>mofetil</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1468 class=n-a></a>0</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1471 class=n-a></a>4.2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1474 class=n-a></a>Nausea, headache, fatigue, paraesthesia, muscle ache, infections,<br class=br>serum creatinine increase, leukopenia, liver enzyme increase,<br class=br>magnesium decrease</td></tr><tr><a name=d39182e1482 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1484 class=n-a></a>Dupilumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1487 class=n-a></a>0–0.55</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1490 class=n-a></a>6.4–21.6</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1493 class=n-a></a>Nasopharyngitis, headache, URTI, injection site reactions,<br class=br>conjunctivitis, AD exacerbation, skin infections, herpes viral infections</td></tr><tr><a name=d39182e1500 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1502 class=n-a></a>Nemolizumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1505 class=n-a></a>0.18</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1508 class=n-a></a>6.6</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1511 class=n-a></a>Nasopharyngitis, AD exacerbation, serum CK increase, URTI,<br class=br>headache, peripheral oedema, impetigo, injection-site reactions</td></tr><tr><a name=d39182e1517 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1519 class=n-a></a>Ustekinumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1522 class=n-a></a>0 </td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1525 class=n-a></a>2.3–2.4</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1528 class=n-a></a>Nasopharyngitis, AD exacerbation</td></tr><tr><a name=d39182e1532 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1534 class=n-a></a>Fezakinumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1537 class=n-a></a>0.42</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1540 class=n-a></a>2.25</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1543 class=n-a></a>Viral URTI</td></tr><tr><a name=d39182e1547 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1549 class=n-a></a>Lebrikizumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1552 class=n-a></a>Not reported<br class=br>(3.2% of patients<br class=br>had ≥1 SAE over<br class=br>20-week study)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1561 class=n-a></a>Not reported<br class=br>(67% of patients had ≥1<br class=br>AE over 20-week study)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1568 class=n-a></a>Infections, skin infections, HSV and HZV infections,<br class=br>conjunctivitis, injection site reactions</td></tr><tr><a name=d39182e1574 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1576 class=n-a></a>Baricitinib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1579 class=n-a></a>0.08%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1582 class=n-a></a>Not reported<br class=br>(59% of patients had ≥1<br class=br>AE over 16-week study)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1589 class=n-a></a>Headache, serum CK increase, AD exacerbation, nasopharyngitis,<br class=br>cellulitis, infections</td></tr><tr><a name=d39182e1595 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1597 class=n-a></a>Tralokinumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1600 class=n-a></a>Not reported<br class=br>(3.3% of patients<br class=br>had ≥1 SAE over<br class=br>12-week study)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1609 class=n-a></a>Not reported<br class=br>(66% of patients had ≥1<br class=br>AE over 12-week study)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d39182e1616 class=n-a></a>Nasopharyngitis, URTI, headache, AD exacerbation, injection site<br class=br>reactions, arthralgia, syncope</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d39182e1626 class=n-a></a><p id=d39182e1628> AD, atopic dermatitis; AE, adverse event; CK, creatine kinase; ESR, erythrocyte sedimentation rate; GI, gastrointestinal; HSV, herpes simplex virus; HZV, herpes zoster virus; LRTI, lower respiratory tract infection; SAE, serious adverse event; URTI, upper respiratory tract infection.</p></div></div></div></div><div class=section><a name=d39182e1635 class=n-a></a><h3 class=section-title>Long-term safety</h3><p class="" id=d39182e1640>Although pre-clinical data suggest that novel systemics may be safer than conventional agents, data on the long-term safety of both systemics in AD populations are limited<sup><a href="#ref-53">53</a></sup>. Although most cases of immunosuppression-related malignancy occur in the context of organ transplantation, studies of patients with inflammatory bowel disease have found an increased risk of lymphoma and non-melanoma skin cancer in those treated with azathioprine<sup><a href="#ref-19">19</a>–<a href="#ref-22">22</a></sup>. Furthermore, there are cases of methotrexate-associated lymphoproliferative disorders, which resolve after withdrawal of the drug, seen in adults with autoimmune diseases, such as rheumatoid arthritis<sup><a href="#ref-54">54</a>,<a href="#ref-55">55</a></sup>. However, these patients have different co-morbidities and take additional medications to those taken by AD patients, which may play a role in these associations. Cases of malignancy have been reported in RCTs of JAK inhibitors in patients with rheumatoid arthritis, and additional data from long-term follow up of patient cohorts is needed to determine the true malignancy risk for JAK inhibitors in AD<sup><a href="#ref-56">56</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d39182e1670>Cost-effectiveness</h2><p class="" id=d39182e1673>Despite novel systemic agents’ promising clinical effectiveness, there is no guarantee that they will be affordable for use within collectively funded healthcare systems. Given that innovations in medicine often impose additional costs when compared to usual care, many healthcare systems around the world now require robust evidence demonstrating that a drug therapy is cost-effective to receive approval for use in clinical practice<sup><a href="#ref-57">57</a>,<a href="#ref-58">58</a></sup>. As such, it is important to consider the evidence needed to develop a cost-effectiveness analysis when formulating data collection strategies for the evaluation of novel systemic treatments. In many countries—including England, Canada, and Australia—cost-effectiveness studies quantify changes in patient health, using the quality-adjusted life year (QALY), which combines mortality and morbidity effects in a single outcome measure<sup><a href="#ref-59">59</a>–<a href="#ref-61">61</a></sup>. Morbidity effects are typically captured using a preference-based measure of health-related quality of life (HRQoL), such as the EQ-5D instrument<sup><a href="#ref-62">62</a></sup>. In addition, data on healthcare resource use and unit costs are needed to calculate the expected healthcare costs associated with the alternative treatments being compared.</p><p class="" id=d39182e1694>A recent systematic review by McManus <i>et al.</i> identified 24 cost-effectiveness studies evaluating interventions for the treatment and prevention of AD<sup><a href="#ref-63">63</a></sup>. One of the key findings in this review was the observed variability in the methods used to combine different forms of evidence (e.g. response rates, HRQoL effects, and resource use), also known as models. In other disease areas, such as rheumatoid arthritis and psoriatic arthritis<sup><a href="#ref-64">64</a></sup>, efforts have been made to reach a consensus on the preferred modelling approach and, as a consequence, standardise the evidence requirements. Similar efforts to establish a preferred modelling approach in the context of AD not only would provide a benchmark against which studies could be assessed but also could be used to inform future data collection strategies.</p><p class="" id=d39182e1708>Another important finding of the systematic review was that the time horizons under examination in many of the studies were of insufficient duration. Ideally, the time horizon for any given cost-effectiveness study should reflect the length of time over which the expected costs and QALYs are likely to differ between alternative treatment strategies<sup><a href="#ref-65">65</a></sup>. Although a challenging proposition given that the follow up of patients even in observational studies continues for only three to five years, the recent appraisal of dupilumab by NICE demonstrates that observational evidence can be used in addition to RCT data to inform the cost-effectiveness analysis of patients<sup><a href="#ref-66">66</a></sup>. Partly based on this health economic analysis, NICE has recommended dupilumab as an option for treating moderate-to-severe AD in adults where the disease has not responded to at least one conventional systemic therapy or where these are contraindicated or not tolerated<sup><a href="#ref-66">66</a></sup>. Interestingly, the economic model considered as part of the NICE appraisal compared dupilumab with topical therapy as best supportive care. The rationale for this was that dupilumab would be positioned after conventional systemics in the treatment pathway for AD, at which point the only other treatment option for patients would be topical therapy<sup><a href="#ref-67">67</a></sup>. Topical therapy might indeed be considered best supportive care once a patient has failed on <i>all</i> conventional systemics; however, this was not the population of patients studied in the dupilumab trials. Indeed, only one trial, LIBERTY-CAFÉ, required participants to have a prior history of ciclosporin use (or contraindication). It is likely that the effectiveness of topical treatment varies in different populations and would be expected to be lower in a population of patients with AD who have failed multiple systemic treatments compared to those who are systemic treatment naïve. A cost-effectiveness model for novel agents should therefore be compared to conventional systemic treatment as best supportive care, even if this is challenging given the current lack of data on the cost-effectiveness of conventional systemics.</p><p class="" id=d39182e1730>The formation of the UK–Irish Atopic eczema Systemic Therapy Register (A*STAR) and other national AD registers within the international TREatment of ATopic eczema registry taskforce (TREAT) represents an important milestone in the collection of data that can be used to inform cost-effectiveness studies for the evaluation of novel AD therapies<sup><a href="#ref-68">68</a>,<a href="#ref-69">69</a></sup>. These treatment registers will be an important data source for the development of future appraisal submissions to regulatory bodies, such as NICE in the UK, given that they collect longitudinal disease severity, quality of life, and healthcare resource use data for every patient recruited and compare conventional and novel therapies alike.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d39182e1743>Indirect comparison method limitations</h2><p class="" id=d39182e1746>The indirect comparison of clinical effectiveness, safety data, and cost-effectiveness drawn from different studies, as presented here, has important limitations. Such comparisons lose the benefits derived from randomisation, such as the balancing of effect modifiers across treatment groups at baseline. Whilst direct comparisons from individual studies may have a low risk of bias (i.e. high internal validity), the inferences drawn from comparisons between studies must be considered observational data and are therefore at higher risk of bias. For example, if the baseline characteristics of the trial participants, such as disease severity, differ, then it is difficult to compare a change in disease severity across trials even where the same disease severity measure was used. Other study design differences will additionally impact on treatment effectiveness, such as the use of concomitant topical corticosteroids.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d39182e1752>Where do we go from here?</h2><p class="" id=d39182e1755>Further head-to-head active comparator studies are needed, such as the ongoing TREatment of severe Atopic eczema Trial (TREAT), which compares ciclosporin and methotrexate in children with moderate-to-severe AD<sup><a href="#ref-70">70</a></sup>. Such studies need to use validated outcome measures that are harmonised to allow for comparisons to be made across studies. The Harmonising Outcome Measures for Eczema (HOME) initiative is an international effort towards a core outcome set for clinical trials in AD that will help to facilitate this<sup><a href="#ref-71">71</a></sup>. Whilst not a current aim of the HOME initiative, reporting would also be useful.</p><p class="" id=d39182e1766>Recognising that randomised controlled trial data directly comparing active treatments will always be limited, network meta-analysis (NMA) will be helpful in plugging this evidence gap. NMA is an approach whereby direct and indirect data can be combined into a single statistical model that takes into account variations between studies and where the assumptions around the similarities between studies can be evaluated<sup><a href="#ref-72">72</a></sup>.</p><p class="" id=d39182e1773>Although novel systemic agents may not vastly improve the clinical effectiveness outcomes in AD, they have the potential to address the more pressing clinical issue of short- and long-term AEs secondary to AD treatment. The limited duration of clinical trials, relatively small sample sizes with respect to safety outcomes, and issues around the generalisability of their findings to the wider patient population mean that data from large ‘real-world’ studies, such as registers and electronic health records, will play an important role in providing evidence to support clinical decision-making. Standardised AE reporting is also needed as we approach an era where safety and tolerability may become more of a differentiator of treatments than clinical effectiveness.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d39182e1779>Conclusion</h2><p class="" id=d39182e1782>Novel biologic and small molecule agents provide great promise for patients with moderate-to-severe AD. While the clinical effectiveness data from these placebo-controlled RCTs are promising, important factors in addition to short- and long-term treatment effectiveness need to be considered, such as drug safety and cost-effectiveness as well as the ability of a drug to alter the natural history of AD. While evidence generation through head-to-head trials would be the preferred route, such trials are likely to remain low in number. Treatment registers and NMA provide important additional tools to better inform evidence-based treatment decisions made by physicians, patients, and regulatory bodies alike. We have entered an exciting era in AD therapeutics but need to travel a much longer journey before the promise of a therapeutic revolution becomes a reality.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d39182e1788>Abbreviations</h2><p class="" id=d39182e1791>AD, atopic dermatitis; AE, adverse event; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; HOME, Harmonising Outcome Measures for Eczema; HRQoL, health-related quality of life; IL, interleukin; JAK, Janus kinase; NICE, National Institute for Health and Care Excellence; NMA, network meta-analysis; QALY, quality-adjusted life year; RCT, randomised controlled trial; SAE, serious adverse event; SCORAD, Scoring Atopic Dermatitis.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d39182e1 class=n-a></a><h2 class=main-title id=d39420>Grant information</h2><p>CF is funded through a UK National Institute for Health Research (NIHR) Career Development Fellowship (CDF-2014-07-037). CF, HA, and ZKJ-L are supported by the NIHR Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=S01 class=n-a></a><a name=S01 class=n-a></a><h2 class=main-title id=d39182e1800>Supplementary material</h2><p class="" id=SF1><b>Supplementary Figure 1. Physician-assessed severity score end points of included trials.</b></p><p class="" id=d39182e1807>Different clinical severity score endpoints were reported across included randomised controlled trials. Many trials did not report the same scores, making indirect comparison of some treatments very difficult. EASI, Eczema Area and Severity Index; IGA, Investigator’s Global Assessment; SASSAD, Six Area Six Sign Atopic Dermatitis; SCORAD, Scoring Atopic Dermatitis.</p><p class="" id=d39182e1810><a target=xrefwindow href="https://f1000researchdata.s3.amazonaws.com/supplementary/17039/b3c1735d-d997-4e03-8704-eac91a1032c5_Suppl_fig1.pdf" id=d39182e1811>Click here to access the data</a></p><p class="" id=SF2><b>Supplementary Figure 2. Treatment effectiveness: physician-assessed severity measures.</b></p><p class="" id=d39182e1819>Eczema Area and Severity Index (EASI) (a) and Scoring Atopic Dermatitis (SCORAD) (b) mean percentage change from baseline up to 64 weeks for systemic agents for which these data were reported. MTX, methotrexate.</p><p class="" id=d39182e1822><a target=xrefwindow href="https://f1000researchdata.s3.amazonaws.com/supplementary/17039/857ca55e-89e8-486b-850a-c434b3612dce_Suppl_fig2.pdf" id=d39182e1823>Click here to access the data</a></p><p class="" id=SF3><b>Supplementary Figure 3. Treatment effectiveness: patient-reported severity measures.</b></p><p class="" id=d39182e1830>The number of included trials reporting patient-reported severity measures. HADS, Hospital Anxiety and Depression Scale; NRS, numerical rating scale; POEM, Patient Oriented Eczema Measure; RCT, randomised controlled trial; SCORAD, Scoring Atopic Dermatitis; VAS, visual analogue scale.</p><p class="" id=d39182e1833><a target=xrefwindow href="https://f1000researchdata.s3.amazonaws.com/supplementary/17039/801a2615-fa15-4c8b-a53a-9c978351de48_Suppl_fig3.pdf" id=d39182e1834>Click here to access the data</a></p><p class="" id=SF4><b>Supplementary Figure 4. Treatment effectiveness: quality of life.</b></p><p class="" id=d39182e1842>The number of included trials reporting quality of life measures. AD, atopic dermatitis; cDLQI, children’s Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; RCT, randomised controlled trial; VAS, visual analogue scale.</p><p class="" id=d39182e1845><a target=xrefwindow href="https://f1000researchdata.s3.amazonaws.com/supplementary/17039/2db742ad-a58d-4c66-a1fe-124d8899b56f_Suppl_fig4.pdf" id=d39182e1846>Click here to access the data</a></p></div><div class=back-section><a name=d39182e1850 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d39657>References</h2><div class="section ref-list"><a name=d39182e1850 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d39182e1857 class=n-a></a>Deckers IA, McLean S, Linssen S, <i> et al.</i>: Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies. <i>PLoS One.</i> 2012; <b>7</b>(7): e39803. <a target=xrefwindow id=d39182e1868 href="http://www.ncbi.nlm.nih.gov/pubmed/22808063">PubMed Abstract </a> | <a target=xrefwindow id=d39182e1871 href="https://doi.org/10.1371/journal.pone.0039803">Publisher Full Text </a> | <a target=xrefwindow id=d39182e1875 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3394782">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727735005"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e1884 class=n-a></a>Thyssen JP, Hamann CR, Linneberg A, <i> et al.</i>: Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. <i>Allergy.</i> 2018; <b>73</b>(1): 214–20. <a target=xrefwindow id=d39182e1895 href="http://www.ncbi.nlm.nih.gov/pubmed/28632893">PubMed Abstract </a> | <a target=xrefwindow id=d39182e1898 href="https://doi.org/10.1111/all.13231">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727735005">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d39182e1911 class=n-a></a>Garg N, Silverberg JI: Association between childhood allergic disease, psychological comorbidity, and injury requiring medical attention. <i>Ann Allergy Asthma Immunol.</i> 2014; <b>112</b>(6): 525–32. <a target=xrefwindow id=d39182e1919 href="http://www.ncbi.nlm.nih.gov/pubmed/24713577">PubMed Abstract </a> | <a target=xrefwindow id=d39182e1922 href="https://doi.org/10.1016/j.anai.2014.03.006">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d39182e1931 class=n-a></a>McAleer MA, Flohr C, Irvine AD: Management of difficult and severe eczema in childhood. <i>BMJ.</i> 2012; <b>345</b>: e4770. <a target=xrefwindow id=d39182e1939 href="http://www.ncbi.nlm.nih.gov/pubmed/22826585">PubMed Abstract </a> | <a target=xrefwindow id=d39182e1942 href="https://doi.org/10.1136/bmj.e4770">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d39182e1951 class=n-a></a>Flohr C, Irvine AD: Systemic therapies for severe atopic dermatitis in children and adults. <i>J Allergy Clin Immunol.</i> 2013; <b>132</b>(3): 774–774.e6. <a target=xrefwindow id=d39182e1959 href="http://www.ncbi.nlm.nih.gov/pubmed/23993356">PubMed Abstract </a> | <a target=xrefwindow id=d39182e1962 href="https://doi.org/10.1016/j.jaci.2013.03.016">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d39182e1972 class=n-a></a>Eichenfield LF, Stein Gold LF: Systemic Therapy of Atopic Dermatitis: Welcome to the Revolution. <i>Sem Cutan Med Surg.</i> 2017; <b>36</b>(4S): S103–S105. <a target=xrefwindow id=d39182e1980 href="http://www.ncbi.nlm.nih.gov/pubmed/29659645">PubMed Abstract </a> | <a target=xrefwindow id=d39182e1983 href="https://doi.org/10.12788/j.sder.2017.051">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d39182e1992 class=n-a></a>Torres T: Atopic Dermatitis: The New Therapeutic Revolution in Dermatology. <i>Acta Med Port.</i> 2017; <b>30</b>(10): 669–70. <a target=xrefwindow id=d39182e2000 href="http://www.ncbi.nlm.nih.gov/pubmed/29268058">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2003 href="https://doi.org/10.20344/amp.9787">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d39182e2012 class=n-a></a>Zirwas MJ: The future is finally here: Advances in the treatment of atopic dermatitis. <i>J Am Acad Dermatol.</i> 2018; <b>78</b>(3 Suppl 1): S25–S27. <a target=xrefwindow id=d39182e2020 href="http://www.ncbi.nlm.nih.gov/pubmed/29248517">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2023 href="https://doi.org/10.1016/j.jaad.2017.12.025">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d39182e2032 class=n-a></a>Simpson EL, Bruin-Weller M, Flohr C, <i> et al.</i>: When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. <i>J Am Acad Dermatol.</i> 2017; <b>77</b>(4): 623–33. <a target=xrefwindow id=d39182e2043 href="http://www.ncbi.nlm.nih.gov/pubmed/28803668">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2046 href="https://doi.org/10.1016/j.jaad.2017.06.042">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734192402"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e2055 class=n-a></a>Seger EW, Wechter T, Strowd L, <i> et al.</i>: Relative efficacy of systemic treatments for atopic dermatitis. <i>J Am Acad Dermatol.</i> 2019; <b>80</b>(2): 411–416.e4. <a target=xrefwindow id=d39182e2066 href="http://www.ncbi.nlm.nih.gov/pubmed/30296535">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2069 href="https://doi.org/10.1016/j.jaad.2018.09.053">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734192402">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d39182e2082 class=n-a></a>Totri CR, Eichenfield LF, Logan K, <i> et al.</i>: Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey. <i>J Am Acad Dermatol.</i> 2017; <b>76</b>(2): 281–5. <a target=xrefwindow id=d39182e2093 href="http://www.ncbi.nlm.nih.gov/pubmed/27855965">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2096 href="https://doi.org/10.1016/j.jaad.2016.09.021">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d39182e2106 class=n-a></a>Proudfoot LE, Powell AM, Ayis S, <i> et al.</i>: The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey. <i>Br J Dermatol.</i> 2013; <b>169</b>(4): 901–9. <a target=xrefwindow id=d39182e2117 href="http://www.ncbi.nlm.nih.gov/pubmed/23855450">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2120 href="https://doi.org/10.1111/bjd.12505">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d39182e2129 class=n-a></a>Taylor K, Swan DJ, Affleck A, <i> et al.</i>: Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists. <i>Br J Dermatol.</i> 2017; <b>176</b>(6): 1617–23. <a target=xrefwindow id=d39182e2140 href="http://www.ncbi.nlm.nih.gov/pubmed/27943248">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2143 href="https://doi.org/10.1111/bjd.15235">Publisher Full Text </a> | <a target=xrefwindow id=d39182e2147 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5516126">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d39182e2156 class=n-a></a>Gerbens LAA, Hamann SAS, Brouwer MWD, <i> et al.</i>: Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial. <i>Br J Dermatol.</i> 2018; <b>178</b>(6): 1288–96. <a target=xrefwindow id=d39182e2167 href="http://www.ncbi.nlm.nih.gov/pubmed/29237228">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2170 href="https://doi.org/10.1111/bjd.16240">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d39182e2179 class=n-a></a>Hughes R, Collins P, Rogers S: Further experience of using azathioprine in the treatment of severe atopic dermatitis. <i>Clin Exp Dermatol.</i> 2008; <b>33</b>(6): 710–1. <a target=xrefwindow id=d39182e2187 href="http://www.ncbi.nlm.nih.gov/pubmed/18681884">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2190 href="https://doi.org/10.1111/j.1365-2230.2008.02832.x">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d39182e2199 class=n-a></a>Buckley DA, Baldwin P, Rogers S: The use of azathioprine in severe adult atopic eczema. <i>J Eur Acad Dermatol Venerol.</i> 1998; <b>11</b>(2): 137–40. <a target=xrefwindow id=d39182e2207 href="http://www.ncbi.nlm.nih.gov/pubmed/9784039">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2210 href="https://doi.org/10.1111/j.1468-3083.1998.tb00766.x">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d39182e2219 class=n-a></a>Sidbury R, Davis DM, Cohen DE, <i> et al.</i>: Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. <i>J Am Acad Dermatol.</i> 2014; <b>71</b>(2): 327–49. <a target=xrefwindow id=d39182e2230 href="http://www.ncbi.nlm.nih.gov/pubmed/24813298">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2233 href="https://doi.org/10.1016/j.jaad.2014.03.030">Publisher Full Text </a> | <a target=xrefwindow id=d39182e2237 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4410179">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d39182e2247 class=n-a></a>Roekevisch E, Spuls PI, Kuester D, <i> et al.</i>: Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. <i>J Allergy Clin Immunol.</i> 2014; <b>133</b>(2): 429–38. <a target=xrefwindow id=d39182e2258 href="http://www.ncbi.nlm.nih.gov/pubmed/24269258">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2261 href="https://doi.org/10.1016/j.jaci.2013.07.049">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d39182e2270 class=n-a></a>Armstrong RG, West J, Card TR: Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. <i>Am J Gastroenterol.</i> 2010; <b>105</b>(7): 1604–9. <a target=xrefwindow id=d39182e2278 href="http://www.ncbi.nlm.nih.gov/pubmed/20104215">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2281 href="https://doi.org/10.1038/ajg.2009.745">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d39182e2290 class=n-a></a>Singh H, Nugent Z, Demers AA, <i> et al.</i>: Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. <i>Gastroenterology.</i> 2011; <b>141</b>(5): 1612–20. <a target=xrefwindow id=d39182e2301 href="http://www.ncbi.nlm.nih.gov/pubmed/21806945">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2304 href="https://doi.org/10.1053/j.gastro.2011.07.039">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d39182e2313 class=n-a></a>Beaugerie L, Brousse N, Bouvier AM, <i> et al.</i>: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. <i>Lancet.</i> 2009; <b>374</b>(9701): 1617–25. <a target=xrefwindow id=d39182e2324 href="http://www.ncbi.nlm.nih.gov/pubmed/19837455">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2327 href="https://doi.org/10.1016/S0140-6736(09)61302-7">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d39182e2336 class=n-a></a>Kandiel A, Fraser AG, Korelitz BI, <i> et al.</i>: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. <i>Gut.</i> 2005; <b>54</b>(8): 1121–5. <a target=xrefwindow id=d39182e2347 href="http://www.ncbi.nlm.nih.gov/pubmed/16009685">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2350 href="https://doi.org/10.1136/gut.2004.049460">Publisher Full Text </a> | <a target=xrefwindow id=d39182e2354 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1774897">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726815273"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e2363 class=n-a></a>Simpson EL, Bieber T, Guttman-Yassky E, <i> et al.</i>: Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. <i>N Engl J Med.</i> 2016; <b>375</b>(24): 2335–48. <a target=xrefwindow id=d39182e2374 href="http://www.ncbi.nlm.nih.gov/pubmed/27690741">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2377 href="https://doi.org/10.1056/NEJMoa1610020">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726815273">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d39182e2391 class=n-a></a>Ariens L, Gadkari A, van Os-Medendorp H, <i> et al.</i>: Comparison of the efficacy of dupilumab versus cyclosporine using EASI thresholds in adult patients with moderate to severe atopic dermatitis. In: <i>International Symposium on Atopic Dermatitis.</i>2018. </span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d39182e2406 class=n-a></a>Harper JI, Ahmed I, Barclay G, <i> et al.</i>: Cyclosporin for severe childhood atopic dermatitis: Short course <i>versus</i> continuous therapy. <i>Br J Dermatol.</i> 2000; <b>142</b>(1): 52–8. <a target=xrefwindow id=d39182e2420 href="http://www.ncbi.nlm.nih.gov/pubmed/10651694">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2424 href="https://doi.org/10.1046/j.1365-2133.2000.03241.x">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d39182e2433 class=n-a></a>Granlund H, Erkko P, Remitz A, <i> et al.</i>: Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. <i>Acta Derm Venereol.</i> 2001; <b>81</b>(1): 22–7. <a target=xrefwindow id=d39182e2444 href="http://www.ncbi.nlm.nih.gov/pubmed/11411908">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2447 href="https://doi.org/10.1080/00015550120235">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d39182e2456 class=n-a></a>Pacor ML, Di Lorenzo G, Martinelli N, <i> et al.</i>: Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: A randomized study. <i>Clin Exp Allergy.</i> 2004; <b>34</b>(4): 639–45. <a target=xrefwindow id=d39182e2467 href="http://www.ncbi.nlm.nih.gov/pubmed/15080819">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2470 href="https://doi.org/10.1111/j.1365-2222.2004.1907.x">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d39182e2479 class=n-a></a>Bemanian MH, Movahedi M, Farhoudi A, <i> et al.</i>: High doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis. <i>Iran J Allergy Asthma Immunol.</i> 2005; <b>4</b>(3): 139–43. <a target=xrefwindow id=d39182e2490 href="http://www.ncbi.nlm.nih.gov/pubmed/17301437">PubMed Abstract </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d39182e2499 class=n-a></a>Schmitt J, Schäkel K, Fölster-Holst R, <i> et al.</i>: Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. <i>Br J Dermatol.</i> 2010; <b>162</b>(3): 661–8. <a target=xrefwindow id=d39182e2510 href="http://www.ncbi.nlm.nih.gov/pubmed/19863501">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2513 href="https://doi.org/10.1111/j.1365-2133.2009.09561.x">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d39182e2523 class=n-a></a>El-Khalawany MA, Hassan H, Shaaban D, <i> et al.</i>: Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. <i>Eur J Pediatr.</i> 2013; <b>172</b>(3): 351–6. <a target=xrefwindow id=d39182e2534 href="http://www.ncbi.nlm.nih.gov/pubmed/23229188">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2537 href="https://doi.org/10.1007/s00431-012-1893-3">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d39182e2546 class=n-a></a>Koppelhus U, Poulsen J, Grunnet N, <i> et al.</i>: Cyclosporine and Extracorporeal Photopheresis are Equipotent in Treating Severe Atopic Dermatitis: A Randomized Cross-Over Study Comparing Two Efficient Treatment Modalities. <i>Front Med (Lausanne).</i> 2014; <b>1</b>: 33. <a target=xrefwindow id=d39182e2557 href="http://www.ncbi.nlm.nih.gov/pubmed/25593907">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2560 href="https://doi.org/10.3389/fmed.2014.00033">Publisher Full Text </a> | <a target=xrefwindow id=d39182e2564 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4292191">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d39182e2573 class=n-a></a>Jin SY, Lim WS, Sung NH, <i> et al.</i>: Combination of glucosamine and low-dose cyclosporine for atopic dermatitis treatment: a randomized, placebo-controlled, double-blind, parallel clinical trial. <i>Dermatol Ther.</i> 2015; <b>28</b>(1): 44–51. <a target=xrefwindow id=d39182e2584 href="http://www.ncbi.nlm.nih.gov/pubmed/25113885">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2587 href="https://doi.org/10.1111/dth.12163">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728880163"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e2596 class=n-a></a>Kim JE, Shin JM, Ko JY, <i> et al.</i>: Importance of concomitant topical therapy in moderate-to-severe atopic dermatitis treated with cyclosporine. <i>Dermatol Ther.</i> 2016; <b>29</b>(2): 120–5. <a target=xrefwindow id=d39182e2607 href="http://www.ncbi.nlm.nih.gov/pubmed/26799345">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2610 href="https://doi.org/10.1111/dth.12333">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728880163">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731603350"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e2623 class=n-a></a>Goujon C, Viguier M, Staumont-Sallé D, <i> et al.</i>: Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial. <i>J Allergy Clin Immunol Pract.</i> 2018; <b>6</b>(2): 562–569.e3. <a target=xrefwindow id=d39182e2634 href="http://www.ncbi.nlm.nih.gov/pubmed/28967549">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2637 href="https://doi.org/10.1016/j.jaip.2017.07.007">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731603350">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d39182e2650 class=n-a></a>Berth-Jones J, Takwale A, Tan E, <i> et al.</i>: Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. <i>Br J Dermatol.</i> 2002; <b>147</b>(2): 324–30. <a target=xrefwindow id=d39182e2661 href="http://www.ncbi.nlm.nih.gov/pubmed/12174106">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2664 href="https://doi.org/10.1046/j.1365-2133.2002.04989.x">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13547"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e2674 class=n-a></a>Meggitt SJ, Gray JC, Reynolds NJ: Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. <i>Lancet.</i> 2006; <b>367</b>(9513): 839–46. <a target=xrefwindow id=d39182e2682 href="http://www.ncbi.nlm.nih.gov/pubmed/16530578">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2685 href="https://doi.org/10.1016/S0140-6736(06)68340-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13547">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/11785956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e2698 class=n-a></a>Schram ME, Roekevisch E, Leeflang MM, <i> et al.</i>: A randomized trial of methotrexate versus azathioprine for severe atopic eczema. <i>J Allergy Clin Immunol.</i> 2011; <b>128</b>(2): 353–9. <a target=xrefwindow id=d39182e2709 href="http://www.ncbi.nlm.nih.gov/pubmed/21514637">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2712 href="https://doi.org/10.1016/j.jaci.2011.03.024">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/11785956">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d39182e2725 class=n-a></a>Oldhoff JM, Darsow U, Werfel T, <i> et al.</i>: Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. <i>Allergy.</i> 2005; <b>60</b>(5): 693–6. <a target=xrefwindow id=d39182e2736 href="http://www.ncbi.nlm.nih.gov/pubmed/15813818">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2739 href="https://doi.org/10.1111/j.1398-9995.2005.00791.x">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d39182e2748 class=n-a></a>Iyengar SR, Hoyte EG, Loza A, <i> et al.</i>: Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. <i>Int Arch Allergy Immunol.</i> 2013; <b>162</b>(1): 89–93. <a target=xrefwindow id=d39182e2759 href="http://www.ncbi.nlm.nih.gov/pubmed/23816920">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2762 href="https://doi.org/10.1159/000350486">Publisher Full Text </a> | <a target=xrefwindow id=d39182e2766 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4161454">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718485867"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e2775 class=n-a></a>Beck LA, Thaçi D, Hamilton JD, <i> et al.</i>: Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. <i>N Engl J Med.</i> 2014; <b>371</b>(2): 130–9. <a target=xrefwindow id=d39182e2786 href="http://www.ncbi.nlm.nih.gov/pubmed/25006719">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2789 href="https://doi.org/10.1056/NEJMoa1314768">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718485867">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725845310"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e2802 class=n-a></a>Thaçi D, Simpson EL, Beck LA, <i> et al.</i>: Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: A randomised, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet.</i> 2016; <b>387</b>(10013): 40–52. <a target=xrefwindow id=d39182e2813 href="http://www.ncbi.nlm.nih.gov/pubmed/26454361">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2816 href="https://doi.org/10.1016/S0140-6736(15)00388-8">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725845310">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727591680"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e2830 class=n-a></a>Blauvelt A, de Bruin-Weller M, Gooderham M, <i> et al.</i>: Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. <i>Lancet.</i> 2017; <b>389</b>(10086): 2287–2303. <a target=xrefwindow id=d39182e2841 href="http://www.ncbi.nlm.nih.gov/pubmed/28478972">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2844 href="https://doi.org/10.1016/S0140-6736(17)31191-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727591680">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732206793"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e2857 class=n-a></a>de Bruin-Weller M, Thaçi D, Smith CH, <i> et al.</i>: Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: A placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). <i>Br J Dermatol.</i> 2018; <b>178</b>(5): 1083–1101. <a target=xrefwindow id=d39182e2868 href="http://www.ncbi.nlm.nih.gov/pubmed/29193016">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2871 href="https://doi.org/10.1111/bjd.16156">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732206793">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726426512"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e2884 class=n-a></a>Khattri S, Brunner PM, Garcet S, <i> et al.</i>: Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. <i>Exp Dermatol.</i> 2017; <b>26</b>(1): 28–35. <a target=xrefwindow id=d39182e2895 href="http://www.ncbi.nlm.nih.gov/pubmed/27304428">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2898 href="https://doi.org/10.1111/exd.13112">Publisher Full Text </a> | <a target=xrefwindow id=d39182e2902 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5502835">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726426512">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727446943"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e2915 class=n-a></a>Saeki H, Kabashima K, Tokura Y, <i> et al.</i>: Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: A randomized, double-blind, placebo-controlled, phase II study. <i>Br J Dermatol.</i> 2017; <b>177</b>(2): 419–427. <a target=xrefwindow id=d39182e2926 href="http://www.ncbi.nlm.nih.gov/pubmed/28338223">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2929 href="https://doi.org/10.1111/bjd.15493">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727446943">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727361836"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e2942 class=n-a></a>Ruzicka T, Hanifin JM, Furue M, <i> et al.</i>: Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. <i>N Engl J Med.</i> 2017; <b>376</b>(9): 826–835. <a target=xrefwindow id=d39182e2953 href="http://www.ncbi.nlm.nih.gov/pubmed/28249150">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2956 href="https://doi.org/10.1056/NEJMoa1606490">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727361836">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733222499"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e2969 class=n-a></a>Kabashima K, Furue M, Hanifin JM, <i> et al.</i>: Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. <i>J Allergy Clin Immunol.</i> 2018; <b>142</b>(4): 1121–1130.e7. <a target=xrefwindow id=d39182e2980 href="http://www.ncbi.nlm.nih.gov/pubmed/29753033">PubMed Abstract </a> | <a target=xrefwindow id=d39182e2983 href="https://doi.org/10.1016/j.jaci.2018.03.018">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733222499">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733454867"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e2997 class=n-a></a>Wollenberg A, Howell MD, Guttman-Yassky E, <i> et al.</i>: Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. <i>J Allergy Clin Immunol.</i> 2019; <b>143</b>(1): 135–141. <a target=xrefwindow id=d39182e3008 href="http://www.ncbi.nlm.nih.gov/pubmed/29906525">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3011 href="https://doi.org/10.1016/j.jaci.2018.05.029">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733454867">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732534768"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e3024 class=n-a></a>Guttman-Yassky E, Brunner PM, Neumann AU, <i> et al.</i>: Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. <i>J Am Acad Dermatol.</i> 2018; <b>78</b>(5): 872–881.e6. <a target=xrefwindow id=d39182e3035 href="http://www.ncbi.nlm.nih.gov/pubmed/29353025">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3038 href="https://doi.org/10.1016/j.jaad.2018.01.016">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732534768">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732615058"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e3051 class=n-a></a>Guttman-Yassky E, Silverberg JI, <i> et al.</i>: Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. <i>J Am Acad Dermatol.</i> 2018; pii: S0190-9622(18)30129-4. <a target=xrefwindow id=d39182e3059 href="http://www.ncbi.nlm.nih.gov/pubmed/29410014">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3062 href="https://doi.org/10.1016/j.jaad.2018.01.018">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732615058">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732534767"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e3075 class=n-a></a>Simpson EL, Flohr C, Eichenfield LF, <i> et al.</i>: Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). <i>J Am Acad Dermatol.</i> 2018; <b>78</b>(5): 863–871.e11. <a target=xrefwindow id=d39182e3086 href="http://www.ncbi.nlm.nih.gov/pubmed/29353026">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3089 href="https://doi.org/10.1016/j.jaad.2018.01.017">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732534767">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d39182e3102 class=n-a></a>Haeck IM, Knol MJ, Ten Berge O, <i> et al.</i>: Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. <i>J Am Acad Dermatol.</i> 2011; <b>64</b>(6): 1074–84. <a target=xrefwindow id=d39182e3113 href="http://www.ncbi.nlm.nih.gov/pubmed/21458107">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3116 href="https://doi.org/10.1016/j.jaad.2010.04.027">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733725123"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e3125 class=n-a></a>Braddock M, Hanania NA, Sharafkhaneh A, <i> et al.</i>: Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review. <i>Drug Saf.</i> 2018; <b>41</b>(5): 489–509. <a target=xrefwindow id=d39182e3136 href="http://www.ncbi.nlm.nih.gov/pubmed/29411337">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3139 href="https://doi.org/10.1007/s40264-017-0636-9">Publisher Full Text </a> | <a target=xrefwindow id=d39182e3143 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5938313">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733725123">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d39182e3157 class=n-a></a>Clarke LE, Junkins-Hopkins J, Seykora JT, <i> et al.</i>: Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin. <i>J Am Acad Dermatol.</i> 2007; <b>56</b>(4): 686–90. <a target=xrefwindow id=d39182e3168 href="http://www.ncbi.nlm.nih.gov/pubmed/17141365">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3171 href="https://doi.org/10.1016/j.jaad.2006.09.011">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d39182e3180 class=n-a></a>Maruani A, Wierzbicka E, Machet MC, <i> et al.</i>: Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis. <i>J Am Acad Dermatol.</i> 2007; <b>57</b>(5 Suppl): S69-71. <a target=xrefwindow id=d39182e3191 href="http://www.ncbi.nlm.nih.gov/pubmed/17938029">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3194 href="https://doi.org/10.1016/j.jaad.2005.09.015">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d39182e3203 class=n-a></a>Lopez-Olivo MA, Tayar JH, Zamora NV, <i> et al.</i>: Malignancies and serious infections in randomised controlled trials of janus kinase inhibitors in patients with rheumatoid arthritis: a systematic review and meta-analysis. <i>Ann Rheum Dis.</i> 2018; <b>77</b>(Suppl 2): 66. <a target=xrefwindow id=d39182e3214 href="https://doi.org/10.1136/annrheumdis-2018-eular.7079">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d39182e3223 class=n-a></a>Drummond M: Future Prospects for Pharmacoeconomics and Outcomes Research in the Emerging Regions. <i>Value Health Reg Issues.</i> 2013; <b>2</b>(1): 3–4. <a target=xrefwindow id=d39182e3231 href="http://www.ncbi.nlm.nih.gov/pubmed/29702849">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3234 href="https://doi.org/10.1016/j.vhri.2013.02.012">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d39182e3243 class=n-a></a>Drummond M: Twenty years of using economic evaluations for drug reimbursement decisions: what has been achieved? <i>J Health Polit Policy Law.</i> 2013; <b>38</b>(6): 1081–102. <a target=xrefwindow id=d39182e3251 href="http://www.ncbi.nlm.nih.gov/pubmed/23974475">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3254 href="https://doi.org/10.1215/03616878-2373148">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d39182e3263 class=n-a></a>National Institute for Health and Care Excellence: Guide to the methods of technology appraisal 2013 [Internet]. National Institute for Health and Care Excellence. 2013; 1–93. <a target=xrefwindow id=d39182e3265 href="http://www.ncbi.nlm.nih.gov/pubmed/27905712">PubMed Abstract </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d39182e3275 class=n-a></a>Lee KM, McCarron CE, Bryan S, <i> et al.</i>: Guidelines for the economic evaluation of health technologies: Canada. 2017; 1–76. <a target=xrefwindow id=d39182e3280 href="https://www.cadth.ca/sites/default/files/pdf/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf">Reference Source</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d39182e3289 class=n-a></a>Pharmaceutical Benefits Advisory Committee (PBAC), Australian Government Department Of Health: Health AGD of Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee. 2016; 1–205. <a target=xrefwindow id=d39182e3291 href="https://pbac.pbs.gov.au/content/information/files/pbac-guidelines-version-5.pdf">Reference Source</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d39182e3300 class=n-a></a>Dolan P: Modeling Valuations for EuroQol Health States. <i>Med Care.</i> 1997; <b>35</b>(11): 1095–108. <a target=xrefwindow id=d39182e3308 href="http://www.ncbi.nlm.nih.gov/pubmed/9366889">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3311 href="https://doi.org/10.1097/00005650-199711000-00002">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730372702"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e3320 class=n-a></a>McManus E, Sach T, Levell N: The Use of Decision-Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal. <i>Pharmacoeconomics.</i> 2018; <b>36</b>(1): 51–66. <a target=xrefwindow id=d39182e3328 href="http://www.ncbi.nlm.nih.gov/pubmed/28864846">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3331 href="https://doi.org/10.1007/s40273-017-0564-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730372702">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d39182e3344 class=n-a></a>Madan J, Ades T, Barton P, <i> et al.</i>: Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party. <i>Rheumatol Ther.</i> 2015; <b>2</b>(2): 113–125. <a target=xrefwindow id=d39182e3355 href="http://www.ncbi.nlm.nih.gov/pubmed/27747536">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3358 href="https://doi.org/10.1007/s40744-015-0020-0">Publisher Full Text </a> | <a target=xrefwindow id=d39182e3362 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4883267">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d39182e3371 class=n-a></a>Sculpher MJ, Claxton K, Drummond M, <i> et al.</i>: Whither trial-based economic evaluation for health care decision making? <i>Health Econ.</i> 2006; <b>15</b>(7): 677–87. <a target=xrefwindow id=d39182e3382 href="http://www.ncbi.nlm.nih.gov/pubmed/16491461">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3385 href="https://doi.org/10.1002/hec.1093">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d39182e3395 class=n-a></a>National Institute for Health and Care Excellence: Dupilumab for treating moderate to severe atopic dermatitis. 2018. <a target=xrefwindow id=d39182e3397 href="https://www.nice.org.uk/guidance/ta534/documents/appraisal-consultation-document">Reference Source</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d39182e3406 class=n-a></a>NICE: Dupilumab for treating moderate to severe atopic dermatitis [Internet]. Technology appraisal guidance [TA534]. 2018. <a target=xrefwindow id=d39182e3408 href="https://www.nice.org.uk/guidance/ta534/resources/dupilumab-for-treating-moderate-to-severe-atopic-dermatitis-pdf-82606900940485">Reference Source</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d39182e3417 class=n-a></a>Gerbens LAA, Apfelbacher CJ, Irvine AD, <i> et al.</i>: TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries. <i>Br J Dermatol.</i> 2018. <a target=xrefwindow id=d39182e3425 href="http://www.ncbi.nlm.nih.gov/pubmed/29761486">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3428 href="https://doi.org/10.1111/bjd.16714">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d39182e3437 class=n-a></a>Spuls PI, Gerbens LAA, Apfelbacher CJ, <i> et al.</i>: The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries. <i>J Invest Dermatol.</i> 2017; <b>137</b>(9): 2014–2016. <a target=xrefwindow id=d39182e3448 href="http://www.ncbi.nlm.nih.gov/pubmed/28558913">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3451 href="https://doi.org/10.1016/j.jid.2017.05.014">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d39182e3460 class=n-a></a>Irvine AD, Jones AP, Beattie P, <i> et al.</i>: A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: The TREatment of severe Atopic eczema Trial (TREAT). <i>Br J Dermatol.</i> 2018; <b>179</b>(6): 1297–1306. <a target=xrefwindow id=d39182e3471 href="http://www.ncbi.nlm.nih.gov/pubmed/29727479">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3474 href="https://doi.org/10.1111/bjd.16717">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/719374335"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d39182e3483 class=n-a></a>Schmitt J, Spuls PI, Thomas KS, <i> et al.</i>: The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. <i>J Allergy Clin Immunol.</i> 2014; <b>134</b>(4): 800–7. <a target=xrefwindow id=d39182e3494 href="http://www.ncbi.nlm.nih.gov/pubmed/25282560">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3497 href="https://doi.org/10.1016/j.jaci.2014.07.043">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/719374335">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d39182e3511 class=n-a></a>Chaimani A, Higgins JP, Mavridis D, <i> et al.</i>: Graphical tools for network meta-analysis in STATA. <i>PLoS One.</i> 2013; <b>8</b>(10): e76654. <a target=xrefwindow id=d39182e3522 href="http://www.ncbi.nlm.nih.gov/pubmed/24098547">PubMed Abstract </a> | <a target=xrefwindow id=d39182e3525 href="https://doi.org/10.1371/journal.pone.0076654">Publisher Full Text </a> | <a target=xrefwindow id=d39182e3529 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3789683">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 31 Jan 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-132.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-132.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK<br/> <sup>2</sup> Centre for Health Economics, University of York, York, UK<br/> <p> <div class=margin-bottom> Helen Alexander <br/> <span>Roles: </span> Conceptualization, Formal Analysis, Investigation, Methodology, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Thomas Patton <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Zarif K. Jabbar-Lopez <br/> <span>Roles: </span> Methodology, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Andrea Manca <br/> <span>Roles: </span> Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Carsten Flohr <br/> <span>Roles: </span> Conceptualization, Formal Analysis, Methodology, Project Administration, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-132/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 31 Jan 2019, 8:132 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.17039.1">https://doi.org/10.12688/f1000research.17039.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Alexander H <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=18628 data-id=17039 data-downloads="" data-views="" data-scholar="10.12688/f1000research.17039.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-132/v1/pdf?article_uuid=71b2e900-06f6-439c-a93b-e4fa9597b348" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.17039.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Alexander H, Patton T, Jabbar-Lopez ZK <em>et al.</em> Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution? [version 1; peer review: 3 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):132 (<a href="https://doi.org/10.12688/f1000research.17039.1" target=_blank>https://doi.org/10.12688/f1000research.17039.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=17039 id=mobile-track-article-signin-17039 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/17039?target=/articles/8-132.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=18628 /> <input name=articleId type=hidden value=17039 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Robert Sidbury</strong>, Dermatology Division, Seattle Children's Hospital, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Gil Yosipovitch</strong>, Department of Dermatology and Cutaneous surgery and Itch Center, Miller School of Medicine, University of Miami, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Steven R Feldman</strong>, Department of Dermatology, Wake Forest School of Medicine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Feldman has received research, speaking and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, BMS, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Ortho Dermatology, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and National Psoriasis Foundation (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 31 Jan 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-132.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-132.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=7912-43433></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=44950-43435></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=15319-43434></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-132/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>31 Jan 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Robert Sidbury</strong>, Dermatology Division, Seattle Children's Hospital, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Gil Yosipovitch</strong>, Department of Dermatology and Cutaneous surgery and Itch Center, Miller School of Medicine, University of Miami, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Steven R Feldman</strong>, Department of Dermatology, Wake Forest School of Medicine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Feldman has received research, speaking and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, BMS, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Ortho Dermatology, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and National Psoriasis Foundation </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-132.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-132/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Novel systemic therapies in atopic dermatitis:...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-132/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-132/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-132/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Alexander H et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-132/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-132",
            templates : {
                twitter : "Novel systemic therapies in atopic dermatitis: what do we need.... Alexander H et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-132/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/17039/18628")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "18628");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "43433": 0,
                           "43434": 0,
                           "43435": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "2903019f-f631-468d-8eaa-0ae25c9010cb";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-132.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-132.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-132.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-132.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-132.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>